MEDICINE DETAILS
Tasigna
Active ingredient: Nilotinib
Neutral reference profile for an independent medicine-access consultancy enquiry about Tasigna (Nilotinib). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Tasigna used for?
Tasigna (nilotinib) is a kinase inhibitor (targeted therapy) indicated to treat chronic myelogenous leukaemia (CML) in:
- Adults who have been newly diagnosed with Philadelphia chromosome–positive (Ph+) CML during the chronic phase (CP; when the condition is developing slowly and the patient has few or no symptoms).
- Adults with Ph+ CML who cannot take other cancer medicines (including imatinib) because they cause side effects or do not work for them during the CP and the accelerated phase (AP; when the cancer cells are dividing rapidly and the patient may have more symptoms).
- Children (aged 1 year and older) with Ph+ CML in CP who:
- Are newly diagnosed, or
- Are no longer benefiting from treatment with a tyrosine kinase inhibitor medicine, or
- Have taken another tyrosine kinase inhibitor medicine and cannot tolerate it.
It is available in capsule form, containing either 75 mg, 150 mg, or 200 mg nilotinib.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Tasigna identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
50 mg · 120 capsules Catalogue organisation: NOVARTIS Pharma GmbH
-
150 mg hard capsules · 112 capsules Catalogue organisation: EurimPharm Arzneimittel GmbH
-
150 mg hard capsules · 120 capsules Catalogue organisation: EurimPharm Arzneimittel GmbH
-
150 mg hard capsules · 392 capsules Catalogue organisation: EurimPharm Arzneimittel GmbH
-
200 mg · 392 capsules Catalogue organisation: NOVARTIS Pharma GmbH
-
200 mg hard capsules · 112 capsules Catalogue organisation: axicorp Pharma B.V.
OFFICIAL SOURCES
Check the Tasigna record at an official source.
Search for “Tasigna” or “Nilotinib”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Tasigna.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Tasigna
01What is Tasigna?＋
This directory record associates the brand name Tasigna with the active ingredient Nilotinib. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Tasigna strengths and packs are recorded?＋
The catalogue currently shows: 50 mg · 120 capsules; 150 mg hard capsules · 112 capsules; 150 mg hard capsules · 120 capsules; 150 mg hard capsules · 392 capsules. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Tasigna?＋
Catalogue records currently name: NOVARTIS Pharma GmbH, EurimPharm Arzneimittel GmbH, axicorp Pharma B.V.. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Tasigna?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Tasigna, payment request, stock guarantee or binding offer.
06Can I buy Tasigna from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.